Institutional shares held 60.9 Million
2.31M calls
1.11M puts
Total value of holdings $2.34B
$88.8M calls
$42.8M puts
Market Cap $2.95B
76,688,496 Shares Out.
Institutional ownership 79.46%
# of Institutions 225


Latest Institutional Activity in VKTX

Top Purchases

Q4 2023
American Century Companies Inc Shares Held: 2.22M ($85.6M)
Q4 2023
Pictet Asset Management Holding Sa Shares Held: 695K ($26.7M)
Q4 2023
Massachusetts Financial Services CO Shares Held: 663K ($25.5M)
Q4 2023
Morgan Stanley Shares Held: 1.51M ($58.2M)
Q4 2023
Viking Global Investors LP Shares Held: 5.15M ($198M)

Top Sells

Q4 2023
Millennium Management LLC Shares Held: 403K ($15.5M)
Q4 2023
Invesco Ltd. Shares Held: 138K ($5.29M)
Q4 2023
State Street Corp Shares Held: 5.73M ($221M)
Q4 2023
Group One Trading, L.P. Shares Held: 22.9K ($882K)
Q4 2023
Two Sigma Investments, LP Shares Held: 119K ($4.58M)

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.


Insider Transactions at VKTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
Monitor Stock Transactions by Investors and Insiders for Free!

Stay Ahead of the Market by Anticipating Purchase and Sale Activities with Early Access, Take Control of Your Trading and Investment Opportunities - Sign Up Now.

View All Transactions

Last 12 Months Summary

Buy / Acquisition
2.22M Shares
From 9 Insiders
Exercise of conversion of derivative security 1.3M shares
Grant, award, or other acquisition 920K shares
Sell / Disposition
2.37M Shares
From 10 Insiders
Open market or private sale 1.67M shares
Payment of exercise price or tax liability 667K shares
Exercise of conversion of derivative security 36.1K shares

Track Institutional and Insider Activities on VKTX

Follow Viking Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VKTX shares.

Notify only if

Insider Trading

Get notified when an Viking Therapeutics, Inc. insider buys or sells VKTX shares.

Notify only if

News

Receive news related to Viking Therapeutics, Inc.

Track Activities on VKTX